Novartis AG Receivables

Novartis AG's receivables stands at $9.8B as of June 2026. That compares with $9.2B in the prior-year period — up 7.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Novartis AG reported $9.8B in receivables versus $9.2B a year earlier — a 7.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $9.2B in the prior-year period — up 7.2% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Novartis AG's receivables evolved across reporting periods, while the comparison chart places NVSEF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Novartis AG's reading of $9.8B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.